Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating II-type diabetes and preparation method of pharmaceutical composition

A composition and technology for diabetes, applied in the directions of drug combination, biochemical equipment and method, pharmaceutical formulation, etc., can solve the problems of accelerating insulin cells, drug dependence, toxic and side effects, etc. Effects with few side effects

Inactive Publication Date: 2016-05-04
孔德华
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the clinical treatment of type Ⅱ diabetes is mainly oral western medicine, common ones are sulfonylureas, biguanides, α-glucosidase inhibitors, insulin sensitizers, glinide insulin secretagogues, etc. Long-term use can easily lead to Drug dependence and toxic side effects, and accelerate the aging of insulin cells, induce a variety of complications, so there is a need for a drug that can regulate eating habits to help reduce the impact of other multiple symptoms on blood sugar, and can control the patient's blood sugar It is one of the difficulties in developing type 2 diabetes mellitus medicines if it is kept within the normal range and is beneficial for long-term use without causing major harm to the body.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] A pharmaceutical composition for treating type II diabetes, which is composed of the following ingredients in parts by weight: 80 parts of crude fiber mixture, 60 parts of phycocyanin, 50 parts of tagetine, 38 parts of diosgenin, 35 parts of rutin, poly 16 parts of ethylene glycol, 15 parts of pyridoxine, 12 parts of flavonoid glycosides, 10 parts of linoleic acid, 10 parts of golden pine bisflavone, 8 parts of kaempferol, 8 parts of quercetin, 7 parts of glutamic acid, lysine 6 parts, tannin 5 parts, flunarizine 5 parts, thiamine 4 parts, mixed enzyme 2 parts.

[0015] Wherein, the crude fiber mixture refers to the mixture of cellulose and hemicellulose in a weight ratio of 3:2. The crude fiber can promote gastrointestinal motility, help digestion, reduce the cholesterol content in blood plasma, and prevent and treat hyperlipidemia and heart disease. Vascular disease, weight control, reducing the incidence of obesity, thereby improving blood sugar production response, ...

Embodiment 2

[0018] A pharmaceutical composition for treating type II diabetes, which is composed of the following components by weight: 115 parts of crude fiber mixture, 75 parts of phycocyanin, 65 parts of tagetine, 57 parts of diosgenin, 52.5 parts of rutin, poly 23 parts of ethylene glycol, 19.5 parts of pyridoxine, 15 parts of flavonoid glycosides, 13 parts of linoleic acid, 12.5 parts of golden pine bisflavone, 10.5 parts of kaempferol, 10 parts of quercetin, 9 parts of glutamic acid, lysine 8 parts, tannin 7.5 parts, flunarizine 6.5 parts, thiamine 5.5 parts, mixed enzyme 4 parts.

[0019]Wherein, the crude fiber mixture refers to the mixture of cellulose and hemicellulose in a weight ratio of 3:2. The crude fiber can promote gastrointestinal motility, help digestion, reduce the cholesterol content in blood plasma, and prevent and treat hyperlipidemia and heart disease. Vascular disease, weight control, reducing the incidence of obesity, thereby improving blood sugar production resp...

Embodiment 3

[0022] A pharmaceutical composition for treating type II diabetes, which is composed of the following ingredients in parts by weight: 150 parts of crude fiber mixture, 90 parts of phycocyanin, 80 parts of tagetine, 76 parts of diosgenin, 70 parts of rutin, poly 30 parts of ethylene glycol, 24 parts of pyridoxine, 18 parts of flavonoid glycosides, 16 parts of linoleic acid, 15 parts of golden pine biflavone, 13 parts of kaempferol, 12 parts of quercetin, 11 parts of glutamic acid, lysine 10 parts, tannin 10 parts, flunarizine 8 parts, thiamine 7 parts, mixed enzyme 6 parts.

[0023] Wherein, the crude fiber mixture refers to the mixture of cellulose and hemicellulose in a weight ratio of 3:2. The crude fiber can promote gastrointestinal motility, help digestion, reduce the cholesterol content in blood plasma, and prevent and treat hyperlipidemia and heart disease. Vascular disease, weight control, reducing the incidence of obesity, thereby improving blood sugar production respo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating II-type diabetes and a preparation method of pharmaceutical composition. The pharmaceutical composition comprises the following ingredients in parts by weight: 80-150 parts of a crude fiber mixture, 60-90 parts of phycocyanobilin, 50-80 parts of patuletin, 38-76 parts of diosgenin, 35-70 parts of rutin, 16-30 parts of polyethylene glycol, 15-24 parts of pyridoxine, 12-18 parts of flavonoid glycosides, 10-16 parts of linoleic acid, 10-15 parts of sciadopitysin, 8-13 parts of kaempferol, 8-12 parts of quercetin, 7-11 parts of glutamic acid, 6-10 parts of lysine, 5-10 parts of tannin, 5-8 parts of flunarizine, 4-7 parts of thiamine and 2-6 parts of mixed enzyme. The pharmaceutical composition disclosed by the invention is a combination of traditional Chinese medicine and western medicines, effectively reduces the blood sugar and improves the glucose tolerance level of a muscle body on the basis of regulating the normal diet, regulates various abnormal indicators of the muscle body, enhances the tolerance of long-term drug use of a diabetic patient and reduces drug side effects. The pharmaceutical composition disclosed by the invention is simple in preparation process and convenient to use and has good clinical popularization significance.

Description

technical field [0001] The invention relates to the technical field of diabetes medication, in particular to a pharmaceutical composition for treating type II diabetes and a preparation method thereof. Background technique [0002] Diabetes is a common chronic metabolic disease characterized by hyperglycemia. It is caused by various pathogenic factors such as genetic factors, immune dysfunction, microbial infection and its toxins, free radical toxins, mental factors, etc. A series of metabolic disorder syndromes such as sugar, protein, fat, water and electrolytes caused by hypofunction and insulin resistance are one of the three most difficult diseases in the world. According to existing statistics, there are about 56 million people with diabetes in my country , and is growing at a rate of about 2 million per year. Diabetes has become the third largest non-communicable disease that endangers human health after cancer and cardiovascular disease. Therefore, it is particularly i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/47A61P3/10A61K31/717A61K31/4025A61K36/28A61K31/58A61K31/7048A61K31/4415A61K31/201A61K31/352A61K31/198A61K31/7024A61K31/495A61K31/51
CPCA61K38/54A61K9/4866A61K31/198A61K31/201A61K31/352A61K31/4025A61K31/4415A61K31/495A61K31/51A61K31/58A61K31/7024A61K31/7048A61K31/717A61K36/28A61K38/44A61K38/47C12Y117/03002C12Y302/01003C12Y302/01004
Inventor 孔德华
Owner 孔德华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products